Evogene Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EVGN Nasdaq 2836 www.evogene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Evogene Ltd.

Evogene Ltd (EVGN) Q1 2026 Earnings Call Highlights: Strategic Collaborations Amid Financial ... - May 28th, 2026 7:00 pm
Evogene Ltd. Q1 2026 Earnings Call Summary - May 20th, 2026 10:43 am
Evogene Shares Decline After Revenue Miss Despite Stronger-Than-Expected Earnings (EVGN) - May 20th, 2026 7:59 am
Evogene Reports First Quarter 2026 Financial Results - May 20th, 2026 5:00 am
Evogene to Present at the 24th Schrödinger European User Group Meeting - May 12th, 2026 6:00 am
Evogene Schedules First Quarter 2026 Financial Results Release - May 7th, 2026 6:00 am
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification - Apr 2nd, 2026 2:01 pm
Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock - Mar 31st, 2026 6:00 am
Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline - Mar 13th, 2026 7:01 pm
Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026 - Mar 9th, 2026 7:00 am
Evogene Ltd. Q4 2025 Earnings Call Summary - Mar 6th, 2026 6:30 am
Evogene: Q4 Earnings Snapshot - Mar 5th, 2026 5:32 am
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 5th, 2026 5:00 am
Evogene Releases CEO Letter to Shareholders - Feb 25th, 2026 6:00 am
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release - Feb 19th, 2026 6:00 am
Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics - Feb 17th, 2026 6:00 am
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases - Feb 11th, 2026 6:00 am
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds - Feb 10th, 2026 11:20 am
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™ - Feb 10th, 2026 6:00 am
Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board - Feb 9th, 2026 6:00 am